Alpha MSH in Ocular Disease
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.
Full description
A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
- 60 years or older
- diagnosis of advanced dry macular degeneration with foveal geographic atrophy
- limited vision or blindness (20/100 or worse) in that eye
- pseudophakia (prior cataract surgery in that eye)
Exclusion Criteria:
Trial design
Primary purpose
Allocation
Interventional model
Masking
54 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal